Pfizers' JAK Inhibitor Approved In Japan For Atopic Dermatitis

The Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved Pfizer Inc's PFE Cibinqo (abrocitinib) for atopic dermatitis (AD).
Related content: Benzinga's Full FDA Calendar.
The approval covers adults and adolescents aged 12 years and older AD patients with inadequate response to existing therapies.
Abrocitinib is an oral, once-daily, Janus kinase 1 (JAK1) inhibitor.
Cibinqo will be available in Japan in doses of 100mg and 200mg.
Regulatory applications for abrocitinib have been submitted to countries worldwide for review, including the U.S., Australia, and the European Union.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization for Cibinqo earlier this month.
Also Read: FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know.
Price Action: PFE stock is down 0.07% at $43.50 during the premarket session on the last check Thursday.

Momentum23.64

Growth97.00

Quality53.60

Value32.29

Short

Medium

Long